Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Bypassing Current Biosecurity Screens with AI Designed Proteins and Closing the Gap with Edge-AI Functional Screening

Created on 22 Oct 2026

Authors

Oualline, G., Noon, M.

Abstract

DNA synthesis machines are vital tools in medicine and research, but they can be misused to produce sequences which are transcribed and translated to produce toxic proteins. Synthesis providers may screen orders for dangerous sequences, but most screening software performs sequence-based alignment, which is vulnerable to AI redesign attacks. Additionally, software-only synthesis screening requires the operator of the machine to be trusted. We present Capiti, an edge-deployed screening system that runs with no internet connection, listens directly to a synthesizer's valve control signals, and aborts a run when it detects incipient pathogenic function. Rather than performing sequence alignment, Capiti is specifically trained to recognize fold. ProteinMPNN was used to generate putatively functional variants of known pathogenic proteins, and a CNN was trained to separate them from active-site knockouts, scrambles, and decoys. We release two models, Capiti-E (known pathogenic proteins) and Capiti-C (resistance genes for antibiotics of last resort), alongside emusynth, a DNA synthesizer emulator. On our test sets, IBBIS commec and SeqScreen incorrectly passed 18.5% and 44.7% of putatively functional pathogenic variants respectively; Capiti passed 0.24%.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 22 Oct 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 20
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement